Pirfenidone and the inflammasome: Getting to the heart of cardiac remodeling

Cardiology (Switzerland)

Volumn 126, Issue 1, 2013, Pages 59-61

  Roche, Patricia ^a   Czubryt, Michael P ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1;

CELL INFILTRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME INHIBITION; FIBROSING ALVEOLITIS; GENE DELETION; GENERAL CONDITION IMPROVEMENT; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART REMODELING; HEART VENTRICLE SIZE; HEART WORK; HYPERTENSION; INFLAMMATORY CELL; LUNG FUNCTION; NONHUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRIER PROTEINS; MALE; MYOCARDIUM; PYRIDONES; VENTRICULAR REMODELING;

EID: 84880182173     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000351983     Document Type: Note

References (21)

1. Wang Y, Wu Y, Chen J, Zhao S, Li H: Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology 2013;126: 1-11.
2. Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata J: Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985.
3. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN: Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995; 6: 779-785.
4. Schelegle ES, Mansoor JK, Giri S: Pirfenidone attenuates bleomycin-induced changes in pulmonary function in hamsters. Proc Soc Exp Biol Med 1997; 3: 392-397.
5. Raghu G, Johnson WC, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069.
6. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
7. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
8. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, CAPACITY Study Group: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
9. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L: Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001; 5: 687-694.
10. Lee KW, Everett TH 4th, Rahmutula D, Guerra JM, Wilson E, Ding C, Olgin JE: Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006; 114: 1703-1712.
11. Van Erp C, Irwin NG, Hoey AJ: Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 2006; 34: 327-334.
12. Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC, Margolin SB: Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol 2004; 53: 141-150.
13. Mirkovic S, Seymour AM, Fenning A, Strachan A, Margolin SB, Taylor SM, Brown L: Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 2002; 135: 961-968.
14. Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE: Pirfenidone mitigates left ventricular fibrosis and function after myocardial infarction and reduces arrhythmias. Heart Rhythm 2010; 7: 1438-1445.
15. Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, Hu S, Wei Y: In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One 2011; 6:e28134.
16. Iyer SN, Gurujeyalakshmi G, Giri SN: Effects of pirfenidone on transforming growth factor-gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291: 367-373.
17. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R: A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-at the transcriptional level. Eur J Pharmacol 2002; 446: 177-185.
18. Zhao R, Yazdi AS, Menu P, Tschopp J: A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469: 221-225.
19. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G: The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10: 241-247.
20. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J: Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001; 107: 1529-1536.
21. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schynder-Candrian S, Schynder B, Akira S, Quesniaux VF, Lagente V, Ryffel B, Couillin I: IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007; 117: 3786-3799.